Results 81 to 90 of about 52,225 (202)

Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies

European Journal of Haematology, Volume 116, Issue 6, Page 907-914, June 2026.
ABSTRACT Introduction Allogeneic stem cell transplantation (allo‐SCT) and donor lymphocyte infusions (DLI) can elicit a graft‐versus‐leukemia (GvL) effect in pediatric patients with hematological malignancies. We report our single‐center experience with prophylactic DLI in high‐risk pediatric patients with leukemia or lymphoma, focusing on feasibility,
Denise Epple, Katja Gall, Luisa Paschke, Hans‐Jochem Kolb, Angela Wawer, Hans Knabe, Irene von Luettichau, Julia Hauer, Uwe Thiel   +8 more
wiley   +1 more source

The NF‐κB Signalling Pathway: Mechanisms, Consequences and Therapeutic Targets

Journal of Cellular and Molecular Medicine, Volume 30, Issue 11, June 2026.
ABSTRACT Nuclear Factor‐kappa B (NF‐κB) is a master transcriptional regulator orchestrating critical cellular processes, predominantly immunity and inflammation. However, its aberrant constitutive activation has emerged as a unifying pathogenetic hallmark across diverse malignancies, autoimmune disorders, and chronic inflammatory diseases.
Bherouz Pourdad, Arash Pourdad
wiley   +1 more source

V280G Mutation, Potential Role in Imatinib Resistance: First Case Report

Clinical Medicine Insights: Oncology, 2017
Introduction: The identification of BCR-ABL expression as the defining leukemogenic event in chronic myeloid leukemia (CML) and the introduction of BCR-ABL tyrosine kinase inhibitors in 2001 have revolutionized disease management, leading to a reduction ...
Ana P Azevedo, Alice Reichert, Celina Afonso, Maria D Alberca, Purificação Tavares, Fernando Lima   +5 more
doaj   +1 more source

Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11)

BMC Cancer, 2004
Background Based on the site of breakpoint in t(9;22) (q34;q11), bcr-abl fusion in leukemia patients is associated with different types of transcript proteins.
Cano Pedro, Luthra Rajyalakshmi, Mundhada Shailendra   +2 more
doaj   +1 more source

Genomic Landscape Analysis of Canine Pulmonary Adenocarcinoma Reveals Candidate Targetable Gene Fusions

Veterinary and Comparative Oncology, Volume 24, Issue 2, Page 393-406, June 2026.
ABSTRACT Spontaneously occurring primary canine pulmonary adenocarcinoma (cPAC) exhibits clinicopathological and molecular similarities to never‐smoker human lung cancers. Shared genomic alterations, including point mutations, indel mutations and copy number changes particularly in HER2 signalling, are significant therapeutic targets, especially for ...
Sharadha Sakthikumar, William P. D. Hendricks, David Rainford, William Selleck, Natalia Briones, Christopher Coggins, Natalie Quan, Victoria Zismann, Gwendolen Lorch, Aleksandar Sekulic, Jeffrey M. Trent   +10 more
wiley   +1 more source

An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature

Case Reports in Hematology, 2018
We report the case of a 76-year-old man who was diagnosed as having chronic myeloid leukemia (CML) with p190 BCR-ABL while receiving treatment for symptomatic multiple myeloma (MM).
Kosuke Miki, Naoshi Obara, Kenichi Makishima, Tatsuhiro Sakamoto, Manabu Kusakabe, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Yasuhisa Yokoyama, Mamiko Sakata-Yanagimoto, Yuichi Hasegawa, Shigeru Chiba   +11 more
doaj   +1 more source

Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells. [PDF]

Iran J Basic Med Sci, 2023
Kamyabi R, Jahandideh A, Panahi N, Muhammadnejad S.   +3 more
europepmc   +1 more source

Expression of p190 BCR-ABL fusion gene in a patient with chronic myeloid leukemia Expressão do rearranjo gênico BCR-ABL com ponto de quebra na região menor do gene BCR em um paciente com leucemia mielóide crônica

Revista Brasileira de Hematologia e Hemoterapia, 2003
A minority of chronic myeloid leukemia cases have breakpoints in the minor cluster region (m-bcr) of the BCR-ABL gene. We report on a patient with Ph-positive and m-bcr breakpoint at diagnosis. She was treated with hydroxyurea and interferon-alpha.
P. V. B. Carvalho, Gustavo J. Lourenço, Maristela Zocca, K. B. B. Pagnano, Irene Lorand-Metze, Carmino A. De Souza, Carmen S. P. Lima   +6 more
doaj   +1 more source

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia. [PDF]

PLoS One, 2022
Maletzke S, Salimi A, Vieri M, Schroeder KM, Schemionek M, Masouleh BK, Brümmendorf TH, Koschmieder S, Appelmann I.   +8 more
europepmc   +1 more source

Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies

The Scientific World Journal, 2006
Imatinib (Gleevec/STI-571/CGP57148B, Novartis) is a small-molecule, tyrosine kinase inhibitor developed to target BCR-ABL, c-Kit, and PDGF-R. Through inhibition of these oncogenic kinases, imatinib is effective in the treatment of BCR-ABL–positive ...
Michael R. Burgess, Charles L. Sawyers
doaj   +1 more source